TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2028

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

TPC induction chemotherapy

TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).

DRUG

GP induction chemotherapy

GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)

Trial Locations (8)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

NOT_YET_RECRUITING

Affiliated cancer hospital and institute of guangzhou medical university, Guangzhou

NOT_YET_RECRUITING

Sun Yat-Sen Memorial Hospital, Guangzhou

NOT_YET_RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Unknown

NOT_YET_RECRUITING

Dongguan people's hospital, Dongguan

NOT_YET_RECRUITING

Foshan First People's Hospital, Foshan

RECRUITING

Peking university shenzhen hospital, Shenzhen

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Sun Yat-sen University

OTHER